Drugs / MVA-NP+M1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00993083 | Jun 2009 → Mar 2010 | influenza | University of Oxford | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-NP+M1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00993083 ↗ |
| Modality | Vaccine | “The novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T-cell responses to internal antigens of the influenza A virus that are conserved across all subtypes,...” PMID 22441650 ↗ Mar 2012 |
| Route | Intramuscular | “via the IM route” NCT00993083 ↗ |